Mammalian target of rapamycin (mTOR) inhibitors, including everolimus and temsirolimus, target the mTOR protein kinase, a critical regulator of cell growth, proliferation, and survival. These inhibitors work by disrupting cellular pathways involved in protein synthesis and autophagy. Everolimus and temsirolimus have primarily been used to treat metastatic renal cell carcinoma (mRCC), though their role has shifted due to the advent of immune checkpoint inhibitors (ICIs). mTOR inhibitors however, still have their role in the treatment of benign urological conditions, such as tuberous sclerosis (TS) related angiomyolipomas.